RankingsPricing
  1. US-listed companies
  2. TAKEDA PHARMACEUTICAL CO LTD
  3. Raw

TAKEDA PHARMACEUTICAL CO LTDTAK

Market cap
P/E ratio
SummaryFinancials
Back to summarized table
Mar 31,
2019		Mar 31,
2020		Mar 31,
2021		Mar 31,
2022		Mar 31,
2023		Mar 31,
2024
Profit (loss)109,01444,290376,171230,166317,038144,197
Depreciation and amortization272,446583,649559,671583,151664,400728,002
Impairment loss10,120101,88225,45254,51564,394150,017
Equity-settled share-based compensation20,08429,12237,66343,37460,67270,871
Loss on sales and disposal of property, plant and equipment45,2209902,109-655-10-6,052
Gain on divestment of business and subsidiaries---7,8296,8077,832
Increase (decrease) in contingent consideration asset (liability)-5,966-18,38759,277-11,1953,99120,757
Finance (income) and expenses, net--137,175-143,110-142,907-106,785-167,757
Share of loss (profit) of investments accounted for using the equity method-----6,473
Income tax expenses (benefit)-14,118-105,044-9,93672,40558,052-91,406
Decrease in trade and other receivables-13,382-34,826-9,316127,29475,12715,104
Increase in inventories58,678137,49225,978-46,148-79,155-115,743
Increase (decrease) in trade and other payables-16,413-29,93236,620125,157-84,804-9,895
Increase (decrease) in provisions-47,063-21,938-49,09958,090-31,899126,901
Increase (decrease) in other financial liabilities--173,400-49,60831,669-18,568
Other, net-73,34722,52037,78641,409-88,778-7,556
Cash generated from operations373,388896,5201,212,6181,263,5281,163,122918,383
Income taxes paid51,536234,612235,801147,724198,439219,941
Tax refunds and interest on tax refunds received6,6277,84434,1147,30112,47317,902
Net cash from operating activities328,479669,7521,010,9311,123,105977,156716,344
Interest received6,30511,4871,1052,9195,05411,161
Dividends received2,7391,3823873,4013,56213,191
Acquisition of property, plant and equipment77,677127,082111,206123,252140,657175,420
Proceeds from sales of property, plant and equipment50,71712,57846,4531,8159628,606
Acquisition of intangible assets56,43790,628125,26262,785493,032305,310
Acquisition of investments17,0997,55112,5968,34110,1516,766
Proceeds From Sale Of Investments65,03549,40274,60416,92122,2548,021
Acquisition of businesses, net of cash and cash equivalents acquired2,958,6864,890-49,672--
Proceeds from sales of business, net of cash and cash equivalents divested85,131461,546530,38828,1967,95819,959
Payments for the settlement of forward exchange contracts designated as net investment hedges-----33,300
Other, net-7,570-14,125-10,343-7,328-3,052-4,003
Net cash used in investing activities-2,835,698292,119393,530-198,125-607,102-463,862
Proceeds From (Payments For) Short-Term Borrowings367,319-351,223-149,043-240,000277,000
Proceeds from issuance of bonds and long-term loans2,795,926496,1901,179,515249,33475,000100,000
Repayments of bonds and long-term loans-701,0571,651,706810,115356,670320,901
Proceeds From The Settlement Of Swaps-----60,063
Acquisition of treasury shares1,1723,7372,14177,53126,9292,326
Interest paid34,914127,211107,350108,207108,555100,375
Dividends paid142,952282,582283,357283,665279,416287,188
Repayments of lease liabilities-30,00039,27039,69443,40154,586
Other, net-14,330-3,893-172-385-9,178-26,102
Net cash used in financing activities2,946,237-1,005,213-1,088,354-1,070,265-709,148-354,416
Net decrease in cash and cash equivalents439,018-43,342316,107-145,285-339,094-101,934
Effect of exchange rate changes on cash and cash equivalents31,26921,76612,50128,75822,92926,204